Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 281-296

  Siddique, Asma ^a   Kowdley, Kris V ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus type 2; Hepatocellular carcinoma; Insulin resistance; Nonalcoholic steatohepatitis

Indexed keywords

4 HYDROXYNONENAL; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; LEPTIN; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RESPIRATORY FACTOR 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESISTIN; SOMATOMEDIN B; SOMATOMEDIN C; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; APOPTOSIS; BODY MASS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; ENERGY EXPENDITURE; FOLLOW UP; GLUCONEOGENESIS; HEPATITIS C; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIPODYSTROPHY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; INSULIN RESISTANCE; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL;

EID: 79959297962     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.007     Document Type: Review

References (103)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9):533-543.
3. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485-1491.
4. Di Bisceglie A.M., Order S.E., Klein J.L., et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991, 86(3):335-338.
5. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
6. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med 2003, 348:1625-1638.
7. Møller H., Mellemgaard A., Lindvig K., et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994, 30(3):344-350.
8. Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12(1):13-21.
9. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004, 10(2 Suppl 1):S69-S73.
10. Larsson S.C., Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007, 97(7):1005-1008.
11. Castagnetta L., Granata O.M., Cocciadiferro L., et al. Sex steroids, carcinogenesis, and cancer progression. Ann N Y Acad Sci 2004, 1028:233-246.
12. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. American Heart Association; National Heart, Lung, and Blood Institute. Circulation 2004, 109(3):433-438.
13. Rajala M.W., Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
14. Harrison S.A. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006, 40:68-76.
15. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
16. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
17. Adami H.O., Chow W.H., Nyrén O., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996, 88(20):1472-1477.
18. Wideroff L., Gridley G., Mellemkjaer L., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89(18):1360-1365.
19. Davila J.A., Morgan R.O., Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54(4):533-539.
20. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
21. Zelber-Sagi S., Nitzan-Kaluski D., Halpern Z., et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006, 26:856-863.
22. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
23. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: Insulin hyper-hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
24. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
25. Ong J.P., Younossi Z.M. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007, 11:1-16.
26. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
27. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661.
28. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26(9):2183-2191.
29. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51(6):1972-1978.
30. Tokushige K., Hashimoto E., Yatsuji S., et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2010, 45(9):960-967.
31. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38(2):420-427.
32. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
33. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010, 5:145-171.
34. Ueki K., Kondo T., Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24:5434-5446.
35. Hotamisligil G.S., Peraldi A., Budavari A., et al. IRS-1 mediated kinase activity in TNF-a and obesity induced insulin resistance. Science 1996, 272:665-668.
36. Poli G. Pathogenesis of liver fibrosis: the role of oxidative stress. Mol Aspects Med 2000, 21:49-98.
37. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005, 42(6):928-940.
38. Canbay A., Friedman S., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
39. Tafani M., Schneider T.G., Pastorino J.G., et al. Cytochrome dependent activation of caspase 3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol 2000, 156:2111-2121.
40. Hu W., Feng Z., Eveleigh J., et al. The major lipid peroxidation product, trans-4 hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002, 23:1781-1789.
41. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20(15):1803-1815.
42. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88(3):323-331.
43. Xu Z., Chen L., Leung L., et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 2005, 102:4120-4125.
44. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
45. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60(1):91-106.
46. Stoll B.A. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 1999, 53:83-87.
47. Alexia C., Fallot G., Lasfer M., et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004, 68:1003-1015.
48. Kaji K., Yoshiji H., Kitade M., et al. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 2008, 22:801-808.
49. Prisco M., Romano G., Peruzzi F., et al. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 1999, 31(2-3):80-89.
50. Scharf J.G., Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003, 35:685-693.
51. Price J.A., Kovach S.J., Johnson T. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 2002, 36(5):1089-1097.
52. Stumpo D.J., Blackshear P.J. Insulin and growth factor effects on c-fos expression in normal and protein kinase C-deficient 3T3-L1 fibroblasts and adipocytes. Proc Natl Acad Sci U S A 1986, 83(24):9453-9457.
53. Boissan M., Beurel E., Wendum D., et al. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 2005, 167:869-877.
54. Malaguarnera M., Di Rosa M., Nicoletti F., et al. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009, 87(7):679-695.
55. Chen J.S., Wang Q., Fu X.H., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009, 39(2):177-186.
56. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
57. Carnero A., Blanco-Aparicio C., Renner O., et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008, 8:187-198.
58. Kandel E.S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999, 253(1):210-229.
59. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 2001, 114(Pt 16):2903-2910.
60. Jee S.H., Ohrr H., Sull J.W., et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293:194-202.
61. Ikejima K., Honda H., Yoshikawa M., et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288-297.
62. Sahai A., Malladi P., Pan X., et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004, 287(5):G1035-G1043.
63. Kitade M., Yoshiji H., Kojima H., et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006 Oct, 44(4):983-991.
64. Myers M.G., Cowley M.A., Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70:537-556.
65. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996, 334:292-295.
66. Vilà L., Roglans N., Alegret M., et al. Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 2008, 48(5):1506-1516.
67. Henriksen J.H., Holst J.J., Møller S., et al. Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal. Hepatology 1999, 29(6):1818-1824.
68. Saxena N.K., Titus M.A., Ding X., et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004, 18(13):1612-1614.
69. Grunfeld C., Zhao C., Fuller J., et al. Endotoxin and cytokines induce expression of leptin, the OB gene product, in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 1996, 97:2152-2157.
70. Kolacynski J.W., Nyce M.R., Considine R.V., et al. Acute and chronic effects of insulin on leptin production in humans in vivo and in vitro. Diabetes 1996, 45:699-701.
71. Hafner S.M., Miettinen H., Karhapaa, et al. Leptin concentrations, sex hormones, and cortisol in non-diabetic men. J Clin Endocrinol Metab 1997, 82:1807-1809.
72. Wang X.J., Yuan S.L., Lu Q., et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 2004, 10(17):2478-2481.
73. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006, 393(Pt 1):7-20.
74. Ramani K., Yang H., Xia M., et al. Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta. Hepatology 2008, 47(2):521-531.
75. Ikejima K., Takei Y., Honda H., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122(5):1399-1410.
76. Moreira R.K. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007, 131(11):1728-1734.
77. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275(4):2247-2250.
78. Yoshiji H., Kuriyama S., Yoshii J., et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52:1347-1354.
79. Elinav E., Abd-Elnabi A., Pappo O., et al. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol 2006, 44(3):529-536.
80. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
81. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6(10):772-783.
82. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8(7):731-737.
83. Hotta K., Funahashi T., Bodkin N.L., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50(5):1126-1133.
84. Zhang H., Cui J., Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010, 2(11):370-376.
85. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002, 51:314-317.
86. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
87. Gruzman A., Babai G., Sasson S. Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 2009, 6(1):13-36.
88. Sandhu M.S., Dunger D.B., Giovannucci E.L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002, 94(13):972-980.
89. Tsuchida A., Yamauchi T., Ito Y., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004, 279:30817-30822.
90. Kondo H., Shimomura I., Matsukawa Y., et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51(7):2325-2328.
91. Chen X., Wang Y. Adiponectin and breast cancer. Med Oncol 2010, [Epub ahead of print].
92. Wei E.K., Giovannucci E., Fuchs C.S., et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97(22):1688-1694.
93. Michalakis K., Williams C.J., Mitsiades N., et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007, 16(2):308-313.
94. Rzepka-Górska I., Bedner R., Cymbaluk-Płoska A., et al. Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol 2008, 29(6):594-597.
95. Kamada Y., Matsumoto H., Tamura S., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47(4):556-564.
96. Wree A., Kahraman A., Gerken G., et al. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 2011, 83(1-2):124-133.
97. Saxena N.K., Fu P.P., Nagalingam A., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139(5):1762-1773. 1773.e1-5.
98. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
99. Cool B., Zinker B., Chiou W., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabolism 2006, 3:403-416.
100. Motoshima H., Goldstein B.J., Igata M., et al. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006, 574(Pt 1):63-71.
101. Wang X., Proud C.G. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006, 21:362-369.
102. Feng Z., Zhang H., Levine A.J., et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005, 102(23):8204-8209.
103. Miyazaki T., Bub J.D., Uzuki M., et al. Adiponectin activates c-Jun NH2 terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 2005, 333(1):79-87.